Published in Am J Physiol Endocrinol Metab on August 31, 2004
Study on Dietary Nutrition Intervention Techniques for Children Obesity | NCT02539836
Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease | NCT01720719
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Human fatty liver disease: old questions and new insights. Science (2011) 8.03
A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet (2006) 7.89
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A (2009) 5.64
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest (2008) 5.05
Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia (2011) 3.97
Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci (2010) 3.72
Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31
Heritability of nonalcoholic fatty liver disease. Gastroenterology (2009) 3.17
The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest (2011) 3.12
Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology (2011) 3.08
Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology (2009) 3.08
In vivo characterization of the liver fat ¹H MR spectrum. NMR Biomed (2010) 3.07
Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology (2008) 3.04
Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut (2008) 3.01
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 2.92
Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A (2006) 2.88
Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol (2011) 2.56
Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2014) 2.49
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology (2011) 2.42
Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut (2011) 2.38
Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes (2009) 2.36
Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology (2007) 2.29
T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging (2011) 2.27
Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point dixon and three-point IDEAL. Magn Reson Med (2008) 2.27
Recent advances in the pathophysiology of nephrolithiasis. Kidney Int (2008) 2.26
Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J Pediatr (2012) 2.23
Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology (2009) 2.19
Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. J Magn Reson Imaging (2009) 2.18
Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology (2010) 2.09
The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol (2010) 2.05
Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia (2009) 2.03
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J (2012) 1.79
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology (2013) 1.78
Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology (2013) 1.77
T1 independent, T2* corrected MRI with accurate spectral modeling for quantification of fat: validation in a fat-water-SPIO phantom. J Magn Reson Imaging (2009) 1.71
Combination of complex-based and magnitude-based multiecho water-fat separation for accurate quantification of fat-fraction. Magn Reson Med (2011) 1.67
Interethnic differences in muscle, liver and abdominal fat partitioning in obese adolescents. PLoS One (2007) 1.66
Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) (2008) 1.64
11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev (2013) 1.60
Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology (2015) 1.60
The genetics of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.55
High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial. Diabetologia (2015) 1.54
The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem (2008) 1.52
Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am (2010) 1.51
Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.49
Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. Am J Clin Nutr (2008) 1.44
Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab (2009) 1.44
Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes (2010) 1.43
Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res (2011) 1.42
Addressing phase errors in fat-water imaging using a mixed magnitude/complex fitting method. Magn Reson Med (2011) 1.41
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol (2009) 1.39
Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis (2013) 1.29
Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism. Diabetologia (2006) 1.29
Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr (2011) 1.29
Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content. Obesity (Silver Spring) (2008) 1.27
Liver fat content determined by magnetic resonance imaging and spectroscopy. World J Gastroenterol (2010) 1.25
Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods. Eur Radiol (2009) 1.23
Ethnic differences in lipoprotein subclasses in obese adolescents: importance of liver and intraabdominal fat accretion. Am J Clin Nutr (2010) 1.23
Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index. Nutr Diabetes (2011) 1.23
The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene. J Neurol (2011) 1.21
Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol (2006) 1.21
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2014) 1.20
Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr (2014) 1.20
Quantitative analysis of T2-correction in single-voxel magnetic resonance spectroscopy of hepatic lipid fraction. J Magn Reson Imaging (2009) 1.19
Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care (2012) 1.19
Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adolescents. Diabetes (2010) 1.17
Metabolically normal obese people are protected from adverse effects following weight gain. J Clin Invest (2015) 1.17
Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation (2009) 1.16
Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. J Pediatr (2012) 1.14
Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) (2010) 1.14
Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol (2012) 1.14
Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol (2013) 1.14
Independent estimation of T*2 for water and fat for improved accuracy of fat quantification. Magn Reson Med (2010) 1.13
Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res (2009) 1.13
Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One (2012) 1.13
Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol (2010) 1.11
CTRP3 attenuates diet-induced hepatic steatosis by regulating triglyceride metabolism. Am J Physiol Gastrointest Liver Physiol (2013) 1.11
Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol (2014) 1.10
Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. J Lipids (2011) 1.09
Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am J Clin Nutr (2014) 1.08
Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes (2012) 1.08
Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring) (2011) 1.07
Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sports Exerc (2010) 1.07
Epidemiology and clinical pathophysiology of uric acid kidney stones. J Nephrol (2014) 1.06
Adipose tissue biology and cardiomyopathy: translational implications. Circ Res (2012) 1.05
Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey. BMC Public Health (2010) 1.05
Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol (2012) 1.05
Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr (2014) 1.05
Parametric exploration of the liver by magnetic resonance methods. Eur Radiol (2009) 1.05
Assessment of the variations in fat content in normal liver using a fast MR imaging method in comparison with results obtained by spectroscopic imaging. Eur Radiol (2007) 1.04
Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol (2014) 1.04
On the performance of T2* correction methods for quantification of hepatic fat content. Magn Reson Med (2011) 1.03
Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol (2014) 1.02
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med (2006) 23.83
Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science (2004) 21.65
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet (2007) 13.78
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet (2005) 12.12
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol (2004) 9.43
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A (2006) 8.20
Human fatty liver disease: old questions and new insights. Science (2011) 8.03
A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet (2006) 7.89
Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med (2010) 6.84
Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81
Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest (2008) 5.05
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest (2003) 4.42
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology (2014) 4.01
PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res (2008) 3.92
Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest (2002) 3.85
Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci (2007) 3.59
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem (2007) 3.45
A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem (2009) 3.41
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet (2006) 3.38
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care (2006) 3.37
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci U S A (2002) 3.09
Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology (2009) 3.08
Effectiveness of a barber-based intervention for improving hypertension control in black men: the BARBER-1 study: a cluster randomized trial. Arch Intern Med (2010) 2.78
Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab (2011) 2.75
Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A (2012) 2.62
ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem (2003) 2.48
Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation (2005) 2.47
Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab (2007) 2.47
A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A (2010) 2.34
Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med (2003) 2.33
Knockout mice lacking steroidogenic factor 1 are a novel genetic model of hypothalamic obesity. Endocrinology (2002) 2.19
Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. Hum Mol Genet (2010) 2.19
African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol (2004) 2.16
Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology (2010) 2.09
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
Midlife fitness and the development of chronic conditions in later life. Arch Intern Med (2012) 2.07
Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest (2002) 2.02
Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci U S A (2013) 1.96
Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab (2009) 1.95
WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics (2006) 1.95
No association between plasma levels of plant sterols and atherosclerosis in mice and men. Arterioscler Thromb Vasc Biol (2004) 1.93
ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2. J Biol Chem (2002) 1.89
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A (2008) 1.86
Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation (2005) 1.84
Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study. Circulation (2006) 1.78
Barbershops as hypertension detection, referral, and follow-up centers for black men. Hypertension (2007) 1.74
Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem (2006) 1.72
A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One (2012) 1.72
Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet (2002) 1.69
Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem (2003) 1.67
Genetic variation in ANGPTL4 provides insights into protein processing and function. J Biol Chem (2009) 1.64
Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem (2004) 1.57
Normal sorting but defective endocytosis of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemia. J Biol Chem (2003) 1.56
Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem (2011) 1.53
Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res (2012) 1.53
Racial and ethnic differences in hospice enrollment among children with cancer. Pediatr Blood Cancer (2013) 1.51
Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest (2012) 1.45
Dual roles for cholesterol in mammalian cells. Proc Natl Acad Sci U S A (2005) 1.43
Sympathetic nerves and the progression of chronic kidney disease during 5/6 nephrectomy: studies in sympathectomized rats. Clin Exp Pharmacol Physiol (2009) 1.42
Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology (2003) 1.42
Sex differences in the association between leptin and CRP: results from the Dallas Heart Study. Atherosclerosis (2006) 1.38
Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J Lipid Res (2002) 1.38
Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes. Hum Mol Genet (2008) 1.37
Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS Study. Atherosclerosis (2007) 1.36
Factors associated with hypertension awareness, treatment, and control in Dallas County, Texas. Arch Intern Med (2008) 1.35
Molecular mechanisms of autosomal recessive hypercholesterolemia. Hum Mol Genet (2002) 1.33
The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem (2005) 1.25
Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J Lipid Res (2003) 1.23
Disruption of cholesterol homeostasis by plant sterols. J Clin Invest (2004) 1.22
Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol (2007) 1.22
Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia. J Clin Invest (2007) 1.22
High-level expression of ABCG5 and ABCG8 attenuates diet-induced hypercholesterolemia and atherosclerosis in Ldlr-/- mice. J Lipid Res (2004) 1.21
Partial resistance to peroxisome proliferator-activated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism. Diabetes (2008) 1.21
The association between midlife cardiorespiratory fitness levels and later-life dementia: a cohort study. Ann Intern Med (2013) 1.21
Missense mutations in ABCG5 and ABCG8 disrupt heterodimerization and trafficking. J Biol Chem (2004) 1.20
T2 measurement of J-coupled metabolites in the human brain at 3T. NMR Biomed (2011) 1.19
Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest (2015) 1.19
Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res (2012) 1.18
Triglyceride-to-high-density-lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men. J Investig Med (2014) 1.16
Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab (2008) 1.15
Preload dependency of left ventricular torsion: the impact of normal saline infusion. Circ Cardiovasc Imaging (2010) 1.14
Bulk magnetic susceptibility effects on the assessment of intra- and extramyocellular lipids in vivo. Magn Reson Med (2002) 1.12
Ludwig's Angina-A Controversial Surgical Emergency: How We Do It. Int J Otolaryngol (2011) 1.12
The modular adaptor protein ARH is required for low density lipoprotein (LDL) binding and internalization but not for LDL receptor clustering in coated pits. J Biol Chem (2004) 1.10
Molecular mechanisms of autosomal recessive hypercholesterolemia. Curr Opin Lipidol (2003) 1.10
Genetics. Simple genetics for a complex disease. Science (2013) 1.10
A phylogenetic survey of biliary lipids in vertebrates. J Lipid Res (2005) 1.08
ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile. J Lipid Res (2005) 1.06
Deletion of GPIHBP1 causing severe chylomicronemia. J Inherit Metab Dis (2011) 1.06
A barber-based intervention for hypertension in African American men: design of a group randomized trial. Am Heart J (2009) 1.05